💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Zuranolone

CHEMBL4105630 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
409.6 g/mol
LogP
4.5
Phase
4

Zuranolone is a neuroactive steroid and positive allosteric modulator of GABA-A receptors that binds to synaptic and extrasynaptic GABA-A receptor complexes, enhancing chloride ion conductance and overall inhibitory neurotransmission to reduce neuronal hyperexcitability associated with mood disorders. It is approved as a two-week oral treatment course for major depressive disorder and postpartum depression, offering rapid onset of antidepressant effects. Unlike SSRIs, it targets GABAergic rather than monoaminergic pathways, potentially addressing neurobiological underpinnings of depression related to GABA deficiency.

الوزن الجزيئي

409,6000 g/mol

LogP

4,50

TPSA

78,90 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Bipolar Disorder Insomnia Stroke Major Depressive Disorder

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@@]1(O)CC[C@H]2[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](C(=O)Cn4cc(C#N)cn4)CC[C@@H]32)C1

                

                

                
                

                    
InChI

                    
InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3/t17-,18+,19-,20-,21+,22-,24-,25+/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C25H35N3O2

                    

                    
                    

                        
HBD / HBA

                        
1 / 4

                    

                    
                    

                        
الروابط القابلة للدوران

                        
3

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
30

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
Zuranolone is a neuroactive steroid and positive allosteric modulator of GABA-A receptors that binds to synaptic and extrasynaptic GABA-A receptor complexes, enhancing chloride ion conductance and overall inhibitory neurotransmission to reduce neuronal hyperexcitability associated with mood disorders. It is approved as a two-week oral treatment course for major depressive disorder and postpartum depression, offering rapid onset of antidepressant effects. Unlike SSRIs, it targets GABAergic rather than monoaminergic pathways, potentially addressing neurobiological underpinnings of depression related to GABA deficiency.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Zuranolone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL4105630.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 86294073.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.